

PRELIMINARY PROGRAMME

26 May 2017

ITALIAN LANGUAGE SYMPOSIUM

PHARMACOLOGY IN INTERVENTIONAL CARDIOLOGY

DAPT AFTER PCI

10.00 **CONTROVERSY 1 - P2Y12 INHIBITION AFTER PCI IN STABLE PATIENTS**

Clopidogrel remains the best option in real life
Direct-acting P2Y12 inhibitors should be preferred
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

10.45 **CONTROVERSY – WHICH P2Y12 INHIBITOR SHOULD WE USE IN ACS?**

What guidelines suggest
What real world registries show
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

LONG-TERM MANAGEMENT OF PCI PATIENTS

11.30 **CONTROVERSY 1 – THERAPY IN HIGH RISK PATIENTS**

Medical therapy optimization with multiple drugs
The newer 'Polypill' is the solution
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

12.15 **CONTROVERSY 2 – ADHERENCE TO DRUGS**

Compliance to treatment as a major determinant of outcome
Strategies to improve patient adherence to treatment
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

12.30 **LUNCH**

ANTICOAGULATION IN PCI PATIENTS WITH ATRIAL FIBRILLATION

14.00 **CONTROVERSY 1 – THE CHOICE OF NOACS AFTER PCI**

Phase 3 trials only must guide drug selection
Real world data help physicians' choice
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

14.45 **CONTROVERSY 2 – NOACS IN PCI AND SURGERY**

Should NOACs be interrupted in case of PCI?
How NOACs should be used in case of surgery?
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

THE FUTURE OF ANTIPLATELETS AND ANTICOAGULANTS AFTER PCI

15.30 **CONTROVERSY 1 – THE FUTURE OF P2Y12 INHIBITION**

Life long dual antiplatelet therapy
Only ticagrelor without aspirin
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

16.15 **CONTROVERSY 2 – THE FUTURE OF NOACS**

Will NOACs and aspirin never be associated?
Will NOACs become indicated also in patients with SCA?
Experts comments (N=5)
Roundtable Discussion With Audience Q&A

**PARALLEL WORKSHOP
ABOUT CLINICAL TRIALS**

09.00 Welcome introduction and course objectives
Juan Carlos Kaski (UK), Giuseppe Rosano (UK), Sven Wassmann (Germany)

SESSION 1. HOW TO DESIGN A CLINICAL TRIAL

09.15 An overview of the different aspects of clinical trials
Claudio Ceconi (Italy)

09.45 Traditional versus novel trial designing
Giuseppe Rosano (UK)

10.15 The objectives, the site, the finance and the role of the ethics committee and
research organization
Basil Lewis (Israel)

SESSION 2. REGULATORY ASPECTS

10.45 Requirements from regulatory agencies: endpoints, comparators, type of studies
Giuseppe M.C. Rosano (UK)

11.15 Post marketing surveillance
Francesco Rossi (Italy)

SESSION 3. HOW TO RUN A TRIAL EFFICIENTLY

11.45 The role of the principal investigator: keys to success, perils and tribulations
Heinz Drexel (Austria)

12.05 The team, the procedures, the monitor and the sponsor

12.25 The role of the research office

12.45 **LUNCH AND NETWORKING**

SESSION 4. TRIAL CATEGORIES

13.45 Randomised controlled trials and registries

14.15 Meta-analyses and systematic reviews

14.45 **SESSION 5: GOOD CLINICAL PRACTICE**

SESSION 6: HOW TO INTERPRET CLINICAL TRIAL DATA

15.15 Examples from recent trials
C. Ceconi (Italy), S. Wassmann (Germany)

SESSION 7: HOW TO WRITE A MANUSCRIPT

15.45 How to make the most of your data
Basil Lewis (Israel), Giuseppe Rosano (UK)

- Selecting the appropriate journal
- How to structure and format the manuscript, organise the data, prepare figures and tables, discuss the findings, write the conclusions and abstract
- Characteristics of a good manuscript
- How to increase the chance of getting it accepted
- Perspectives of an Editor-in-Chief

16.15 Certificates and closing remarks
Juan Carlos Kaski (UK), Giuseppe M.C. Rosano (UK), Sven Wassmann (Germany)

17.00 **EuroCVP 2017 OPENING CEREMONY**

18.00 **END OF DAY 1**

27 May 2017

NEW TARGETS IN THE PREVENTION OF CARDIOVASCULAR DISEASE

Chairs: Basil Lewis (Israel), Stefan Agewall (Norway)

09.00 The pharmacological and non-pharmacological approach to cardiovascular prevention
Massimo Piepoli (Italy)

09.45 The management of lipid profile according to the ESC Guidelines
Heinz Drexel (Austria)

10.30 Management of altered glucose metabolism
Itamar Raz (Israel)

DIABETES MELLITUS: A CARDIOVASCULAR DISEASE

Chairs: Stefan Anker (Germany), Massimo Piepoli (Italy)

11.00 Cardiovascular risk in diabetics
Gianluigi Savarese (Sweden)

11.30 Lenient or intensive control of glycaemia?
Itamar Raz (Israel)

12.00 Effective at last – The new glucose-lowering drugs that reduce cardiovascular events
Thomas Walther (Ireland)

12.30 **LUNCHEON SYMPOSIUM**
PHARMACOLOGY OF ANTI-ISCHAEMIC THERAPY

HOW TO TREAT THE DIFFICULT PATIENT?

Chairs: Claudio Ceconi (Italy), Juan Carlos Kaski (UK)

14.30 Elderly patients with heart failure co-morbidities
Andrew Coats (UK)

15.00 Patients with acute coronary syndromes receiving oral anticoagulants
Sven Wassmann (Germany)

15.30 Ischaemic heart failure with renal and/or liver failure
Claudio Ceconi (Italy)

Joint Session with the HEART FAILURE ASSOCIATION



PHARMACOTHERAPY OF HEART FAILURE

Chairs: Petar Seferovic (Serbia), Thomas Walther (Ireland)

16.00 How to implement the pharmacological therapy of patients with HFrEF
Giuseppe Rosano (UK)

16.30 Optimisation of RAASi – How can we manage K+
Lars Lund (Sweden)

17.00 The treatment of patients with advanced heart failure
Marco Metra (Italy)

17.30 **END OF DAY 2**

28 May 2017

UPDATE ON ORAL ANTICOAGULATION

Chairs: Juan Tamargo (Spain), Thomas Schmidt (Denmark)

09.00 NOACs for patients with venous thromboembolism and atrial fibrillation
Alexander Niessner (Austria)

09.30 How can we individualise NOACs in everyday practice?
Giuseppe Rosano (UK)

10.00 Anticoagulation in the difficult patient: how to choose the right drug
Sven Wassmann (Germany)

10:30 **OPEN COFFEE BREAK WITH PANEL DISCUSSION**

NOAC antidotes. How relevant for clinical practice?

Panel: Basil Lewis (Israel), Alexander Niessner (Austria),
Giuseppe Rosano (UK), Sven Wassmann (Germany)

Current status of antidotes and reversal agents for NOAC
Sven Wassmann (Germany)

MODERN MANAGEMENT OF CHRONIC ISCHAEMIC HEART DISEASE

Chairs: Maurizio Volterrani (Italy) – Dan Atar (Norway)

- 11.00 Targets for the modern pharmacologic treatment of chronic ischaemic heart disease
Juan Carlos Kaski (UK)
- 11.30 Combination therapy for the optimal management of chronic stable angina
Giuseppe Rosano (UK)
- 12.00 Heart rate and cardiac metabolism optimisation
Maurizio Volterrani (Italy)
- 12.30 Closing discussion
- 13.00 **END OF DAY 3**

GENERAL INFORMATION

CONGRESS VENUE

NH VITTORIO VENETO
Corso d'Italia, 1 - 00198 Rome (Italy)
Tel. +39 06 84951

OFFICIAL LANGUAGE:

The official language of the Meeting will be English, with the exception the Italian of language Symposium.

ORGANIZING SECRETARIAT



MICOM Srl
Via B. Verro, 12 - 20141 – Milan (Italy)
Tel. +44 02 89 51 88 95
Fax +44 02 89 51 89 54
E-mail: info@eurocvp.com
Website: www.eurocvp.com

SCIENTIFIC SECRETARIAT

EUROPEAN SOCIETY OF CARDIOLOGY

The European Heart House
Les Templiers - 2035 Route des Colles - CS 80179 BIOT
06903 - Sophia Antipolis Cedex (France)

